Dr. Panpan Zhang, MD

Dr. Panpan Zhang works as a Medical Oncologist specialized in gastrointestinal carcinomas and neuroendocrine neoplasms (NENs) at the Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, in Beijing, China. She gained her MD degree in Medical Oncology and currently is a PhD student at the Peking University. Her major research interests are neuroendocrine tumors (NETs) and gastrointestinal carcinomas. From 2014, her clinical work and research has focused on the development of innovative treatments for NETs. She has just returned from a short-term fellowship at the Erasmus MC, The Netherlands. She is actively involved in several prospective clinical trials in NETs and gastrointestinal cancers, aimed at achieving a better understanding of these malignancies and improving clinical management of patients. In addition, she is a member of the multidisciplinary team at Beijing Cancer Hospital and the Chinese Neuroendocrine Tumor Society (CNETS).

Relevant Publications

Panpan Zhang, Wei Wang, Ming Lu, Jie Li, et al. Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population-based study. Cancer Med. 2018;7(9):4361-4370. https://www.ncbi.nlm.nih.gov/pubmed/30062861

Panpan Zhang, Jiangyuan Yu, Lin Shen, Jie Li, et al. Clinical and Prognostic Value of PET/CT imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms. Contrast Media Mol Imaging. 2018;2018:2340389.
https://www.ncbi.nlm.nih.gov/pubmed/29681780

Luohai Chen, Lin Zhou, Meng Zhang, Liang Shang, Panpan Zhang, et al. Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs. BMC Cancer. 2017;17(1):521.
https://www.ncbi.nlm.nih.gov/pubmed/28778195

Panpan Zhang, Ming Lu, Lin Shen, Jie Li, et al. Clinical features of patients with pancreatic neuroendocrine neoplasms: a retrospective analysis of 61 cases in a cancer center. J. Int J Clin Exp Med. 2017;10(3):4897-4904.
http://www.ijcem.com/files/ijcem0045112.pdf

Panpan Zhang, Lin Shen. Circulating Biomarkers for Nonfunctional Gastroenteropancreatic Neuroendocrine Neoplasm: where do we stand? Oncology and Translational Medicine. 2017;3(1):15-19.
http://otm.tjh.com.cn/ch/reader/view_abstract.aspx?file_no=OTM160186&flag=1

Panpan Zhang, Ming Lu, Lin Shen. Advances of the bone metastasis of the neuroendocrine neoplasm. Chinse Clinical Oncology. 2016;21(2):182-186 (in Chinese).
http://manu65.magtech.com.cn/Jwk3_lczlxzz/CN/abstract/abstract1958.shtml

Panpan Zhang, Lin Shen. Implementation of multidisciplinary team in the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasm. Zhonghua Wei Chang Wai Ke Za Zhi. 2016;19(11):1205-1210 (in Chinese).
https://www.ncbi.nlm.nih.gov/pubmed/27928786

Dr. Kira Oleinikov, MD

Dr. Kira Oleinikov is a senior physician at the Neuroendocrine Tumor Unit & ENETS Center of Excellence, Endocrinology Department, Division of Medicine of the Hadassah-Hebrew University Medical Center, in Jerusalem, Israel. Following an initial training in molecular biology, Dr. Kira Oleinikov successfully completed her internal medicine and endocrinology specialization in 2017. In August 2018, Kira joined the Neuroendocrine Tumor Unit & ENETS Center of Excellence team at Hadassah-Hebrew University Medical Center in Jerusalem, one of the major clinical and research units in NETs internationally, as a full-time consultant. Kira is actively involved in all programs running at the Hadassah NET unit, including clinical programs (seeing NET patients in the clinic/departments or as part of the regular patient follow-up/recruitment in clinical trials); NET laboratory research; teaching programs (both medical and post-graduate students at the Hadassah Faculty of Medicine); NET patient's advocacy group activities, and more. Kira is a member of the European Neuroendocrine Tumor Society (ENETS) and the Israeli Endocrine Society. Kira's sharp intellectual abilities have driven her to a variety of academic achievements during her fellowship in molecular biology at the Hebrew University. She is continuously involved in the diagnostic and therapeutic decision-making process of NET patients with a variety of tumors, and established herself already as a highly prepared clinician in the field. Nowadays, Kira's main research interest is focused on the evaluation of different treatment approaches to pancreatic NETs, as well as in developing new biomarkers for lung carcinoids. Additionally, she spends a significant part of her time in the unit basic research laboratory, aiming to examine the possible anti-tumorigenic effect of different drug combinations in a NET liver metastasis mouse model, in an attempt to overcome drug-resistance. At a personal level, Kira brings to NET CONNECT a combination of knowledge, tenacity, and good communications skills.

Relevant Publications

Sherman S, Oleinikov K, Mouallem M. Allergic reaction induced by steroid therapy. Harefuah. 2013;152(1):21-2, 60, 59.
https://www.ncbi.nlm.nih.gov/pubmed/23461021

Mayan H, Carmon V, Oleinikov K, London S, Halevy R, Holtzman EJ, Tenenbaum-Rakover Y, Farfel Z, Hanukoglu A. Hypercalciuria in familial hyperkalemia and hypertension with KLHL3 mutations. Nephron. 2015;130(1):59-65.
https://www.ncbi.nlm.nih.gov/pubmed/25925082

Oleinikov K, Saiegh L, Shechner C, Sheikh-Ahmad M, Maria Reut, Laniado M, Matter I, Gaspar T, Sachner R. Clinical experience with adrenal venous sampling in differentiating unilateral vs. bilateral primary hyperaldosteronism. Poster presented at the 46th Annual Meeting of the Israel Endocrine Society, Ramat Gan, 2017.
https://www.ies.org.il/images/AbstractsBook2017.pdf

Oleinikov K, Dancour A, Epshtein J, Benson A, Mazeh H, Tal I, Livovsky D M, Goldin E, Gross D J, Jacob H, Grozinsky-Glasberg S. Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) as a Novel Therapeutic Approach in Highly-Selected Pancreatic Neuroendocrine Neoplasms (pNENs) Patients: Preliminary Report. 2018 [Submitted].

Dr. Elettra Merola, MD, PhD

Dr. Elettra Merola is a gastroenterologist who is currently working at Santa Chiara Hospital in Trento (Italy). She received her medical degree in 2005 from Campus Bio Medico (Rome, Italy). She completed her residency in Gastroenterology in 2009, and her PhD in Digestive Oncology at Sapienza University (Rome, Italy) in 2013, where she worked until May 2017. She was awarded in March 2017 with the ENETS CoE Academy Fellowship Grant for a cooperative project developed at the FAU Erlangen University (Germany), where she worked with Prof. Pavel until April 2018. She has been visiting researcher in different institutes (Charité University, Germany; University of Illinois at Chicago, Temple University, Philadelphia, USA). She has led several cooperative studies aimed at improving clinical management of patients affected by neuroendocrine tumors, and has been a member of the Knowledge Network.

Relevant Publications

Panzuto F, Cicchese N, Partelli S, Rinzivillo M, Capurso G, Merola E, et al. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. PLoS One. 2017;12(6):e0179445.
https://www.ncbi.nlm.nih.gov/pubmed/28644861

Merola E, Panzuto F, Fave GD. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(28):46624-46634.
https://www.ncbi.nlm.nih.gov/pubmed/28402955

Merola E, Pavel M, Panzuto F, et al. Functional imaging in the follow-up of entero-pancreatic neuroendocrine tumors: clinical usefulness and indications. J Clin Endocrinol Metab. 2017;102(5):1486-1494.
https://www.ncbi.nlm.nih.gov/pubmed/28324047

Panzuto F, Merola E, Pavel M, et al. Stage IV gastro-entero-pancreatic neuroendocrine neoplasms: a risk score to predict clinical outcome. Oncologist. 2017;22(4):409-415.
https://www.ncbi.nlm.nih.gov/pubmed/28232598

Panzuto F, Merola E, Rinzivillo M, et al. Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. Pancreas. 2014;43(2):212-218.
https://www.ncbi.nlm.nih.gov/pubmed/24518498

NET Italian Guidelines AIOM-ITANET. Neoplasie Neuroendocrine gastroenteropancreatiche; edizione 2013-2015.
http://ita-net.org/news/5.

Merola E, Sbrozzi-Vanni A, Capurso G, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 2012;95:207-213.
https://www.ncbi.nlm.nih.gov/pubmed/21811050

Dr. Francesca Spada, MD

Dr. Francesca Spada is a Medical Oncologist at the Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumor, European Institute of Oncology (IEO IRCCS, Milan, Italy). She has been part of this team for the last eight years. Francesca completed her specialty in Medical Oncology in 2011 at the University of Sassari. She is involved in clinical management of patients affected by neuroendocrine neoplasms (NENs), educational activities in NENs, and she is also involved in NENs translational research projects. In January 2019, she plans to finish her PhD in Translation and Experimental Medicine at the University of Insubria (Varese, Italy), focusing on the development of mixed adeno-neuroendocrine carcinomas (MANECs). She is also responsible for the IEO Neuroendocrine Multidisciplinary Group activity as quality coordinator.

She is a member of the Italian Association of Medical Oncology (AIOM) while also serving on the AIOM Young Directive Board. She is a member of the Directive Board of the Italian Association of Neuroendocrine Tumors (Ita.NET). She is also member of the European Neuroendocrine Tumor Society (ENETS), the North American Neuroendocrine Society (NANETS), and the European Society of Medical Oncology (ESMO).

In the last three years, Francesca co-authored several peer-reviewed studies, in particular a notable Italian multicenter analysis of oxaliplatin-based chemotherapy in NET patients as a lead author, and an Italian multicenter study of octreotide and everolimus as first-line therapy in patients with well-differentiated NETs.

Relevant Publications

Rinzivillo M, Fazio N, Pusceddu S, Spallanzani A, Ibrahim T, Campana D, Marconicini R, Partelli S, Badalamenti G, Brizzi MP, Catena L, Schinzari G, Carnaghi C, Berardi R, Faggiano A, Antonuzzo L, Spada F, Gritti S, Femia D, Gelsomino F, Bongiovanni A, Ricci S, Brighi N, Falconi M, Delle Fave G, Panzuto F. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology. 2018;18(2):198-203.
https://www.ncbi.nlm.nih.gov/pubmed/29361429

Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Cremonini N, Davi M, Funicelli L, Massironi S, Spada F, Toscano V, Versari A, Zini M, Falconi M, Oberg K. Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms.
Endocr Metab Immune Disord Drug Targets. 2018;18(5):419-449.
https://www.ncbi.nlm.nih.gov/pubmed/29237387

Fazio N, Ungaro A, Spada F, Cella CA, Pisa E, Barberis M, Grana C, Zerini D, Bertani E, Ribero D, Funicelli L, Bonomo G, Ravizza D, Guarize J, De Marinis F, Petrella F, Del Signore E, Pelosi G, Spaggiari L. The role of multimodal treatment in patients with advanced lung neuroendocrine tumors. J Thorac Dis. 2017;9(Suppl 15):S1501-S1510.
https://www.ncbi.nlm.nih.gov/pubmed/29201453

Martins D, Spada F, Lambrescu I, Rubino M, Cella C, Gibelli B, Grana C, Ribero D, Bertani E, Ravizza D, Bonomo G, Funicelli L, Pisa E, Zerini D, Fazio N; IEO ENETS Center of Excellence for GEP NETs. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors. Target Oncol. 2017;12(5):611-622.
https://www.ncbi.nlm.nih.gov/pubmed/28634872

Berardi R, Torniai M, Pusceddu S, Spada F, Ibrahim T, Brizzi MP, Antonuzzo L, Ferolla P, Panzuto F, Silvestris N, Partelli S, Ferretti B, Freddari F, Gucciardino C, Testa E, Concas L, Murgioni S, Bongiovanni A, Zichi C, Riva N, Rinzivillo M, Brunetti O, Giustini L, Di Costanzo F, Delle Fave G, Fazio N, De Braud F, Falconi M, Cascinu S. Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors Cancer Med. 2017;6(7):1493-1499.
https://www.ncbi.nlm.nih.gov/pubmed/28547856

Lambrescu I, Fica S, Martins D, Spada F, Cella C, Bertani E, Rubino M, Gibelli B, Grana C, Bonomo G, Funicelli L, Ravizza D, Pisa E, Zerini D, Ungaro A, Fazio N; IEO ENETS Center of Excellence for GEP NET. Metronomic and metronomic-like therapies in neuroendocrine tumors – Rationale and clinical perspectives. Cancer Treat Rev. 2017;55:46-56.
https://www.ncbi.nlm.nih.gov/pubmed/28314176

Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T, Campana D, Fazio N, Delle Fave G. Pancreas. Everolimus in Pancreatic Neuroendocrine Carcinomas G3. 2017;46(3):302-305.
https://www.ncbi.nlm.nih.gov/pubmed/28099254

Bertani E, Fazio N, Radice D, Zardini C, Grana C, Bodei L, Funicelli L, Ferrari C, Spada F, Partelli S, Falconi M. Resection of the primary tumor followed by peptide receptor radionuclide therapy as upfront strategy for the treatment of G1-G2 pancreatic neuroendocrine tumors with unresectable liver metastases. Ann Surg Oncol. 2016;23(Suppl 5):981-989.
https://www.ncbi.nlm.nih.gov/pubmed/27613553

Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, Pisa E, Barberis M, Vanoli A, Buzzoni R, Pusceddu S, Concas L, Sessa F, Solcia E, Capella C, Fazio N, La Rosa S. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. Neuroendocrinology. 2017;104(1):85-93.
https://www.ncbi.nlm.nih.gov/pubmed/26943788

Spada F, Antonuzzo L, Marconcini R, Radice D, Antonuzzo A, Ricci S, Di Costanzo F, Fontana A, Gelsomino F, Luppi G, Nobili E, Galdy S, Cella CA, Sonzogni A, Pisa E, Barberis M, Fazio N. Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors.
Neuroendocrinology. 2016;103(6):806-814.
https://www.ncbi.nlm.nih.gov/pubmed/26789262

Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. 2015;20(5):570.
https://www.ncbi.nlm.nih.gov/pubmed/25956900

Koumarianou A, Kaltsas G, Kulke MH, Oberg K, Strosberg JR, Spada F, Galdy S, Barberis M, Fumagalli C, Berruti A, Fazio N. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects. Neuroendocrinology. 2015;101(4):274-288.
https://www.ncbi.nlm.nih.gov/pubmed/25924937

Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, Ricci S, Aieta M, Pucci F, Valente M, Bianco N, Mauri CM, Spada F. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study. Cancer. 2014;120(16):2457-2463.
https://www.ncbi.nlm.nih.gov/pubmed/24752410

Fazio N, Spada F, Giovannini M. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view. Cancer Treat Rev. 2013; 39(3):270-274.
https://www.ncbi.nlm.nih.gov/pubmed/22819619

Dr. Wouter Zandee, MD

Dr. Wouter Zandee graduated from medical school in 2010 at the Leiden University with a thesis on the surgical treatment of medullary thyroid carcinoma. Thereafter he started his training to become an internist-endocrinologist. He is currently a fellow in endocrinology at the Erasmus Medical Center, Rotterdam, focusing on several types of endocrine tumors. In the neuroendocrine tumor department he is a sub-investigator of multicenter trials. Concurrently he is pursuing a PhD on neuroendocrine tumors, focusing on biomarkers, treatment of hormonal syndromes (mainly with 177Lu-DOTATATE) and quality of care.

Relevant Publications

Zandee WT et al. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumors. European Journal for Endocrinology 2016.
https://www.ncbi.nlm.nih.gov/pubmed/27491374

Zandee WT et al. Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. Clinical Endocrinology 2017.
https://www.ncbi.nlm.nih.gov/pubmed/28464233

Zandee WT et al. Effect of hypersecretory syndromes on neuroendocrine tumor prognosis. Endocrine Related Cancer 2017.
https://www.ncbi.nlm.nih.gov/pubmed/28483790

Blazevic A, Zandee WT et al. Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumour. Endocrine Related Cancer 2018.
https://www.ncbi.nlm.nih.gov/pubmed/29255095

Hofland J, Zandee WT & de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nature Endocrine Reviews 2018.
https://www.ncbi.nlm.nih.gov/pubmed/30158549

de Hosson LD, Veenendaal LMV, Schuller Y, Zandee WT et al. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastro-intestinal neuroendocrine tumours according to ESMOMCBS and ASCO framework. Annals of Oncology 2017.
https://www.ncbi.nlm.nih.gov/pubmed/29045525

Zandee WT & WW de Herder. The evolution of neuroendocrine tumor treatment, reflected by ENETS guidelines. Neuroendocrinology 2018.
https://www.ncbi.nlm.nih.gov/pubmed/29320780

Dr. Rachel van Leeuwaarde, MD, PhD

Dr. Rachel van Leeuwaarde is an endocrinologist at the department of Endocrine Oncology at the University Medical Center of Utrecht, The Netherlands. She graduated cum laude from the Vrije University in Amsterdam and completed her Internal Medicine residency at the University Medical Center of Utrecht. During her endocrinology fellowship she developed an interest in endocrine oncology. Currently she is a staff member at the department of Endocrine Oncology at the University Medical Center of Utrecht and the Antoni van Leeuwenhoek hospital in Amsterdam.

During her PhD trajectory on Multiple Endocrine Neoplasia Type 1, she completed a master in Epidemiology at the Julius Center for Health Sciences and Primary Care at the University Medical Center of Utrecht. Her PhD study was on “The impact of screening in Multiple Endocrine Neoplasia type 1”.

Dr. van Leeuwaarde’s research focusses on endocrine tumor syndromes such as Multiple Endocrine Neoplasia type 1 & 2 and Von Hippel Lindau disease with a special interest in screening and the health related quality of life in these syndromes.

Relevant Publications

van Leeuwaarde RS, de Laat JM, Pieterman CRC, Dreijerink K, Vriens MR, Valk GD. The future: medical advances in MEN1 therapeutic approaches and management strategies. Endocr Relat Cancer (2017) 24: doi:10.1530/ERC-17-0225
https://www.ncbi.nlm.nih.gov/pubmed/28768698

Nell S, van Leeuwaarde RS, Pieterman CRC, de Laat JM, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, L. M, Bisschop PH, et al. No Association of Blood Type O with Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. J Clin Endocrinol Metab (2015) jc.2015-2615. doi:10.1210/jc.2015-2615
https://www.ncbi.nlm.nih.gov/pubmed/26247473

Pieterman CRC, de Laat JM, Twisk JWR, van Leeuwaarde RS, de Herder WW, Dreijerink KMA, Hermus ARMM, Dekkers OM, van der Horst-Schrivers ANA, Drent ML, et al. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group. J Clin Endocrinol Metab (2017) 102: doi:10.1210/jc.2017-00372
https://www.ncbi.nlm.nih.gov/pubmed/28938468

van Leeuwaarde RS, Pieterman CRC, Bleiker EMA, Dekkers OM, van der Horst-Schrivers AN, Hermus AR, de Herder WW, Drent ML, Bisschop PH, Havekes B, et al. High fear of disease occurrence is associated with low quality of life in patients with Multiple Endocrine Neoplasia type 1 (MEN1): Results from the Dutch MEN1 Study Group. J Clin Endocrinol Metab (2018) 103:2354–2361. doi:10.1210/jc.2018-00259
https://www.ncbi.nlm.nih.gov/pubmed/29618015

van Treijen MJC, van Beek D-J, van Leeuwaarde RS, Vriens MR, Valk GD. Diagnosing Nonfunctional Pancreatic NETs in MEN1: The Evidence Base. J Endocr Soc (2018) 2:1067–1088. doi:10.1210/js.2018-00087
https://www.ncbi.nlm.nih.gov/pubmed/30202829

van Leeuwaarde RS, van Nesselrooij BPM, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Vriens MR, et al. Impact of delay in diagnosis in outcomes in MEN1: results from the Dutch MEN1 study group. J Clin Endocrinol Metab (2016) 101:jc.2015-3766. doi:10.1210/jc.2015-3766
https://www.ncbi.nlm.nih.gov/pubmed/26751192

Dr. Faidon Laskaratos, MBBS, MSc, MRCP

Dr. Laskaratos is a specialist registrar in gastroenterology and general internal medicine in London, UK. He has an interest in neuroendocrine tumours and is currently a clinical research fellow in the Neuroendocrine Tumour Unit, ENETS Centre of Excellence of the Royal Free Hospital. Dr. Laskaratos qualified from the University of Athens in 2008 and was awarded a prize from the Academy of Athens for graduating first in rank out of 250 students. He subsequently completed his early medical training in the London Deanery and entered into gastroenterology specialty training within the North Central/East Thames rotation. Dr. Laskaratos also has a special interest in medical education and has been awarded an MSc in education from University College London.

Relevant Publications

Laskaratos FM, Walker M, Wilkins D, et al. Evaluation of clinical prognostic factors and further delineation of the effect of mesenteric fibrosis on survival in advanced midgut neuroendocrine tumours. Neuroendocrinology. 2018. doi: 10.1159/000493317.
https://www.ncbi.nlm.nih.gov/pubmed/30153671

Laskaratos FM, Caplin M. Treatment challenges in and outside a network setting: Gastrointestinal neuroendocrine tumours. Eur J Surg Oncol. 2018. doi: 10.1016/j.ejso.2018.03.012.
https://www.ncbi.nlm.nih.gov/pubmed/29685756

Laskaratos FM, Diamantopoulos L, Walker M, et al. Prognostic Factors for Survival among Patients with Small Bowel Neuroendocrine Tumours Associated with Mesenteric Desmoplasia. Neuroendocrinology. 2018;106(4):366-80.
https://www.ncbi.nlm.nih.gov/pubmed/29320779

Laskaratos FM, Rombouts K, Caplin M, et al. Neuroendocrine tumors and fibrosis: An unsolved mystery? Cancer. 2017;123(24):4770-90.
https://www.ncbi.nlm.nih.gov/pubmed/29112233

Laskaratos FM, Walker M, Naik K, et al. Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours. Br J Cancer. 2016;115(11):1321-7.
https://www.ncbi.nlm.nih.gov/pubmed/27811856

Laskaratos FM, Parry D, El-Mileik H. The Educational Value Of Post-Take Ward Rounds For Senior Trainees. Ulster Med J. 2016;85(2):113-7.
https://www.ncbi.nlm.nih.gov/pubmed/27601766

Tsoutsouki J, Laskaratos FM, Mason S, et al. A rare cause of GI bleeding in a patient with cutaneous vascular malformations. Gut. 2016;65(11):1792.
https://www.ncbi.nlm.nih.gov/pubmed/26809732

Laskaratos FM, Vlachou E, Luong TV, et al. Endoscopic resection of a giant ileal inflammatory fibroid polyp by retrograde double-balloon enteroscopy. Endoscopy. 2016;48 Suppl 1 UCTN:E14-5.
https://www.ncbi.nlm.nih.gov/pubmed/26800193

Harpham-Lockyer L, Laskaratos FM, Berlingieri P, et al. Role of virtual reality simulation in endoscopy training. World J Gastrointest Endosc. 2015;7(18):1287-94.
https://www.ncbi.nlm.nih.gov/pubmed/26675895

Ratneswaren A, Laskaratos FM, Kumar A, et al. Rectal bleeding due to rectal erosion of vaginal mesh. Ann Gastroenterol. 2015;28(4):498.
https://www.ncbi.nlm.nih.gov/pubmed/26424465

Laskaratos FM, Wallace D, Gkotsi D, et al. The educational value of ward rounds for junior trainees. Med Educ Online. 2015;20:27559.
https://www.ncbi.nlm.nih.gov/pubmed/25907002

Laskaratos FM, Toumpanakis C, Clark I, et al. Diagnosis of polypoid portal hypertensive enteropathy due to superior mesenteric vein thrombosis by capsule endoscopy and double-balloon enteroscopy. Endoscopy. 2014;46 Suppl 1 UCTN:E592-3.
https://www.ncbi.nlm.nih.gov/pubmed/25502255

Laskaratos FM, Hamilton M, Novelli M, et al. A rare cause of abdominal pain, diarrhoea and GI bleeding. Idiopathic myointimal hyperplasia of the mesenteric veins (IMHMV). Gut. 2015;64(2):214, 350.
https://www.ncbi.nlm.nih.gov/pubmed/25342827

Laskaratos FM, Gillmore R, Clark I, et al. Dark macules in the upper gastrointestinal tract: an ominous sign. Dig Liver Dis. 2014;46(12):1133.
https://www.ncbi.nlm.nih.gov/pubmed/25131639

Laskaratos FM, Gkotsi D, Panteliou E. A critical review of the core medical training curriculum in the UK: A medical education perspective. JRSM Open. 2014;5(1):2042533313514049.
https://www.ncbi.nlm.nih.gov/pubmed/25057366

Laskaratos FM, Gkotsi D, Panteliou E, et al. The educational value of ward rounds in conveying knowledge and developing trainees’ clinical skills. Br J Hosp Med (Lond). 2014;75(3):162-5.
https://www.ncbi.nlm.nih.gov/pubmed/24621633

Laskaratos FM, Walker M, Walker M, et al. Predictive factors for early mortality after percutaneous endoscopic and radiologically-inserted gastrostomy. Dig Dis Sci. 2013;58(12):3558-65.
https://www.ncbi.nlm.nih.gov/pubmed/23975341

Goodhand JR, Kamperidis N, Rao A, Laskaratos F, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(3):513-9.
https://www.ncbi.nlm.nih.gov/pubmed/21604328

Lazaris DP, Laskaratos FJ, Lascaratos GJ. Surgical diseases of the womb according to Aetius of Amida (6th century A.D.). World J Surg. 2009;33(6):1310-7.
https://www.ncbi.nlm.nih.gov/pubmed/19343416

Stavrianeas NG, Ioannou ET, Laskaratos FM. Constantine the Great and leprosy: fact or fiction? Clin Dermatol. 2009;27(1):139-41. https://www.ncbi.nlm.nih.gov/pubmed/19095160

Dr. Angela Lamarca, MD, PhD, MSc

Dr. Angela Lamarca is a Medical Oncologist (MD, PhD, MSc), specialised in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumours (NETs). She completed her training in Medical Oncology (including her PhD) in Spain (Hospital Universitario La Paz, Madrid). She moved to The Christie NHS Foundation Trust (Manchester, United Kingdom) in 2013, where she completed a 4-year fellowship programme in HPB and NETs; during this period she received funding from ESMO (European Society for Medical Oncology) Translational Fellowship Programme, Pancreatic Cancer Research Fund and The Spanish Society of Medical Oncology (SEOM) Fellowship Grant Programme. Dr. Lamarca has completed a Master’s Degree in Molecular Biology of Cancer and a second Master’s Degree in Biostatistics. She was awarded with an American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award in 2017 and was appointed as a Consultant in Medical Oncology at The Christie NHS Foundation Trust in May 2017, where she continues her Clinical and Translational Research career in HPB and NETs. She is actively involved in clinical trial design with a special interest in NETs and HPB, focused on achieving a better understanding of these malignancies and identification of new therapies for improving patients’ outcome. Dr. Angela Lamarca is a member of the EORTC Gastrointestinal Cancer Group and a faculty member of the ESMO Neuroendocrine, Endocrine Neoplasms and CUP Group.

Relevant Publications

Angela Lamarca, Jorge Barriuso, Mairéad G McNamara, Juan W Valle. Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. Cancer Treatment Reviews 2018;70:168-177. doi: 10.1016/j.ctrv.2018.09.002. https://www.ncbi.nlm.nih.gov/pubmed/30218788

Angela Lamarca, Lynne McCallum, Christina Nuttall, Jorge Barriuso, Alison Backen, Melissa Frizziero, Rebecca Leon, Was Mansoor, Mairéad G McNamara, Richard A. Hubner, Juan W Valle. Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumours: results of a prospective observational study. Expert Review of Gastroenterology & Hepatology 2018 Jul;12(7):723-731. doi: 10.1080/17474124.2018.1489232.
https://www.ncbi.nlm.nih.gov/pubmed/29923433

Angela Lamarca, Daisuke Nonaka, Wolfgang Breitwieser, Garry Ashton, Jorge Barriuso, Mairéad G McNamara, Sharzad Moghadam, Jane Rogan, Wasat Mansoor, Richard A Hubner, Christopher Clark, Bipasha Chakrabarty, Juan W Valle. PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. Oncotarget 2018 Feb 12;9(19):14922-14938. doi: 10.18632/oncotarget.24464.
https://www.ncbi.nlm.nih.gov/pubmed/29599916

Angela Lamarca, Jorge Barriuso, Matthew Kulke, Ivan Borbath, Heinz-Josef Lenz, Jean Luc Raoul, Neal J Meropol, Catherine Lombard-Bohas, James Posey, Sandrine Faivre, Eric Raymond, Juan W Valle. Determination of an optimal response cutoff able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. British Journal of Cancer 2017 Jan;118(2):181-188. doi: 10.1038/bjc.2017.402.
https://www.ncbi.nlm.nih.gov/pubmed/29161241

Juan W. Valle, Angela Lamarca, Lipika Goyal, Jorge Barriuso, Andrew X. Zhu. New horizons for precision medicine in biliary tract cancers. Cancer Discovery 2017 Aug 17. doi: 10.1158/2159-8290.CD-17-0245.
https://www.ncbi.nlm.nih.gov/pubmed/28818953

Lamarca A, Pritchard DM, Westwood T, Papaxoinis G, Nonaka D, Vinjamuri S, Valle JW, Manoharan P, Mansoor W. 68Gallium DOTANOC-PET Imaging in Lung Carcinoids: Impact on Patients’ Management. Neuroendocrinology. 2017 Apr 12. doi: 10.1159/000472717.
https://www.ncbi.nlm.nih.gov/pubmed/28399530

Angela Lamarca, Thomas Walter, Marianne Pavel, Ivan Borbath, Patricia Freis, Barbara Nuñez, Alexa Childs, Mairéad G McNamara, Richard A Hubner, Rocio Garcia-Carbonero, Tim Meyer, Juan W. Valle, Jorge Barriuso. Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients with High-Grade Gastrointestinal Neuroendocrine Carcinomas. J Natl Cancer Inst. 2017 Jan 27;109(5). pii: djw277. doi: 10.1093/jnci/djw277).
https://www.ncbi.nlm.nih.gov/pubmed/28130474

Fotouhi O, Kjellin H, Larsson C, Hashemi J, Barriuso J, Juhlin CC, Lu M, Höög A, Pastrián LG, Lamarca A, Soto VH, Zedenius J, Mendiola M, Lehtiö J, Kjellman M. Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors. The Journal of Clinical Endocrinology and Metabolism. 2016 Oct;101(10):3616-3627.
https://www.ncbi.nlm.nih.gov/pubmed/27459532

Childs A, Kirkwood A, Edeline J, Luong TV, Watkins J, Lamarca A, Alrifai D, Nsiah-Sarbeng P, Gillmore R, Mayer A, Thirlwell C, Sarker D, Valle JW, Meyer T. Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. Endocrine Related Cancer. 2016 Jul;23(7):563-70. doi: 10.1530/ERC-16-0099.
https://www.ncbi.nlm.nih.gov/pubmed/27412968

Angela Lamarca, Emma Elliott, Jorge Barriuso, Alison Backen, Mairéad G. McNamara, Richard Hubner, Juan W. Valle. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: a lost cause? Cancer Treatment Reviews, 2016 Mar;44:26-41. doi: 10.1016/j.ctrv.2016.01.005.
https://www.ncbi.nlm.nih.gov/pubmed/26855376

Lamarca A, Nonaka D, Lopez Escola C, Hubner RA, O’Dwyer S, Chakrabarty B, Fulford P, Valle JW. Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence. Neuroendocrinology. 2016;103(5):500-17. doi: 10.1159/000440725.
https://www.ncbi.nlm.nih.gov/pubmed/26356507

Angela Lamarca, Sarah Benafif, John Bridgewater, Paul Ross, Juan W Valle. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention worth pursuing in patients with luminal disease. European Journal of Cancer 2015; Sep;51(13):1694-703. doi: 10.1016/j.ejca.2015.05.018.
https://www.ncbi.nlm.nih.gov/pubmed/26066735

Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Annals of Oncology. 2014. Dec;25(12):2328-38. doi: 10.1093/annonc/mdu162.
https://www.ncbi.nlm.nih.gov/pubmed/24769639

Dr. Alia Munir, MD, PhD

Dr. Alia Munir trained in Medicine at the University of Wales College of Medicine and began her basic clinical training in Cardiff and South Wales. She then began her specialist training in Guy’s and St Thomas’ London and later completed her higher medical training in Diabetes, Endocrinology and General Internal Medicine at Sheffield Teaching Hospitals (STH). She was awarded The Society for Endocrinology Clinical Trust Research Fellowship and obtained a PhD in Professor Newell-Prices’ laboratory, focussing on RNA interference as a Therapy for Cushing’s Disease, leading to a patent and orphan drug designation. She was also awarded the Yorkshire Enterprise Fellowship. She was chair of the Young Endocrinologists Scientific Steering Committee for the Society for Endocrinology during this time.

She was appointed Consultant in Diabetes and Endocrinology in Pinderfields Hospital, Mid Yorkshire 2011-2015. She was also appointed Consultant Endocrinologist in STH and coordinated Sheffield’s successful European Neuroendocrine Tumour Society Centre of Excellence award in 2016. She has led in a joint working partnership with Novartis and has been part of the 4th Wave Education programme with Ipsen.

Dr. Munir’s main clinical interests are in neuroendocrinology and high-risk diabetic pregnancy; she is responsible for general medical inpatients and participates in the medical take.

Relevant Publications

Church D, Cardoso L, Kay RG, Williams CL, Freudenthal B, Clarke C, Harris J, Moorthy M, Karra E, Gribble FM, Reimann F, Burling K, Williams AJK, Munir A, Jones TH, Führer D, Moeller LC, Cohen M, Khoo B, Halsall D, Semple R. Assessment and Management of Anti-insulin Autoantibodies in Varying Presentations of Insulin Autoimmune Syndrome. J Clin Endocrinol Metab. 2018 [Epub ahead of print].
https://www.ncbi.nlm.nih.gov/pubmed/30085133

Novodvorsky P, Walkinshaw E, Rahman W, Gordon V, Towse K, Mitchell S, Selvarajah D, Madhuvrata P, Munir A. Experience with FreeStyle Libre Flash glucose monitoring system in management of refractory dumping syndrome in pregnancy shortly after bariatric surgery. Endocrinol Diabetes Metab Case Rep. 2017;pii:17-0128.
https://www.ncbi.nlm.nih.gov/pubmed/29302329

Kassim S, Munir A. Perioperative management of diabetes and corticosteroid supplementation. Surgery. 2017;35(10):596-600.
https://www.surgeryjournal.co.uk/article/S0263-9319(17)30151-5/pdf

Kerr DE, Wenham T, Munir A. Endocrine problems in the critically ill 1: diabetes and glycaemic control. BJA Education. 2017;17(11):370-376.
https://bjaed.org/article/S2058-5349(17)30176-2/fulltext

Hernández-Ramírez LC, Gabrovska P, Dénes J, Stals K, Trivellin G, Tilley D, Ferrau F, Evanson J, Ellard S, Grossman AB, Roncaroli F, Gadelha MR, Korbonits M; International FIPA Consortium. Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. J Clin Endocrinol Metab. 2015;100(9):E1242-1254.
https://www.ncbi.nlm.nih.gov/pubmed/26186299

Munir A, Newell-Price J. Management of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology. 2010;92 Suppl 1:82-85.
https://www.ncbi.nlm.nih.gov/pubmed/20829624

Munir A, Newell-Price J. Nelson’s Syndrome.
Arq Bras Endocrinol Metabol. 2007;51(8):1392-1396.
https://www.ncbi.nlm.nih.gov/pubmed/18209878

Munir A, Choudhary P, Harrison B, Heller S, Newell-Price J.
Continuous glucose monitoring in patients with insulinoma.
Clin Endocrinol (Oxf). 2008;68(6):912-918.
https://www.ncbi.nlm.nih.gov/pubmed/18088393

Dr. Louis de Mestier, MD

Dr. Louis de Mestier serves as Specialist Registrar in the Department of Gastroenterology-Pancreatology at the ENETS Centre of Excellence of Beaujon University Hospital in Clichy, France. He completed his postgraduate specialist diplomas in Hepato-Gastroenterology and Digestive Oncology at the University of Reims, France. He has completed a Master of Science in Cancer Biology and is a PhD student at the University of Paris 7. His clinical interests focus on gastrointestinal cancers and especially neuroendocrine tumors. His main areas of clinical and basic research include pancreatic and intestinal NETs and especially personalized treatment and biomarkers. He is an active member of the European (ENETS) and French (GTE) NET networks, for which he is leading several prospective studies. He has published several clinical papers on NET, including 17 papers as first or second author since 2015.

Relevant Publications

de Mestier L, Zappa M, Hentic O, Vilgrain V, Ruszniewski P. Liver transarterial embolizations in metastatic neuroendocrine tumors. Rev Endocr Metab Disord. 2017 Dec;18(4):459-471. doi: 10.1007/s11154-017-9431-2.
https://www.ncbi.nlm.nih.gov/pubmed/28975561

de Mestier L, Cros J, Neuzillet C, Hentic O, Egal A, Muller N, Bouché O, Cadiot G, Ruszniewski P, Couvelard A, Hammel P. Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Neuroendocrinology. 2017;105(4):412-425. doi: 10.1159/000475527.
https://www.ncbi.nlm.nih.gov/pubmed/28803232

de Mestier L, Pasmant E, Fleury C, Brixi H, Sohier P, Féron T, Diebold MD, Clauser E, Cadiot G; Groupe d’Étude des Tumeurs Endocrines. Familial small-intestine carcinoids: Chromosomal alterations and germline inositol polyphosphate multikinase sequencing. Dig Liver Dis. 2017 Jan;49(1):98-102. doi: 10.1016/j.dld.2016.10.007.
https://www.ncbi.nlm.nih.gov/pubmed/27825921

Moryoussef F, de Mestier L, Belkebir M, Deguelte-Lardière S, Brixi H, Kianmanesh R, Hoeffel C, Cadiot G. Impact of Liver and Whole-Body Diffusion-Weighted MRI for Neuroendocrine Tumors on Patient Management: A Pilot Study. Neuroendocrinology. 2017;104(3):264-272. doi: 10.1159/000446369.
https://www.ncbi.nlm.nih.gov/pubmed/27120316

Lardière-Deguelte S, de Mestier L, Appéré F, Vullierme MP, Zappa M, Hoeffel C, Noaves M, Brixi H, Hentic O, Ruszniewski P, Cadiot G, Panis Y, Kianmanesh R. Toward a Preoperative Classification of Lymph Node Metastases in Patients with Small Intestinal Neuroendocrine Tumors in the Era of Intestinal-Sparing Surgery. Neuroendocrinology. 2016;103(5):552-9. doi: 10.1159/000441423.
https://www.ncbi.nlm.nih.gov/pubmed/26445315

Cros J, Moati E, Raffenne J, Hentic O, Svrcek M, de Mestier L, Sbidian E, Guedj N, Bedossa P, Paradis V, Sauvanet A, Panis Y, Ruszniewski P, Couvelard A, Hammel P. Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors. Neuroendocrinology. 2016;103(5):495-9. doi: 10.1159/000440724.
https://www.ncbi.nlm.nih.gov/pubmed/26335532

de Mestier L, Hentic O, Cros J, Walter T, Roquin G, Brixi H, Lombard-Bohas C, Hammel P, Diebold MD, Couvelard A, Ruszniewski P, Cadiot G. Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study. Ann Intern Med. 2015 May 19;162(10):682-9. doi: 10.7326/M14-2132.
https://www.ncbi.nlm.nih.gov/pubmed/25984844

de Mestier L, Lardière-Deguelte S, Brixi H, O’Toole D, Ruszniewski P, Cadiot G, Kianmanesh R. Updating the surgical management of peritoneal carcinomatosis in patients with neuroendocrine tumors. Neuroendocrinology. 2015;101(2):105-11. doi: 10.1159/000371817.
https://www.ncbi.nlm.nih.gov/pubmed/25592061

de Mestier L, Gaujoux S, Cros J, Hentic O, Vullierme MP, Couvelard A, Cadiot G, Sauvanet A, Ruszniewski P, Richard S, Hammel P. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place. Ann Surg. 2015 Aug;262(2):384-8. doi: 10.1097/SLA.0000000000000856.
https://www.ncbi.nlm.nih.gov/pubmed/25185468

de Mestier L, Walter T, Brixi H, Lombard-Bohas C, Cadiot G. Sunitinib achieved fast and sustained control of VIPoma symptoms. Eur J Endocrinol. 2015 Jan;172(1):K1-3. doi: 10.1530/EJE-14-0682.
https://www.ncbi.nlm.nih.gov/pubmed/25305306

de Mestier L, Dromain C, d’Assignies G, Scoazec JY, Lassau N, Lebtahi R, Brixi H, Mitry E, Guimbaud R, Courbon F, d’Herbomez M, Cadiot G. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer. 2014 Apr 28;21(3):R105-20. doi: 10.1530/ERC-13-0365.
https://www.ncbi.nlm.nih.gov/pubmed/24351682

de Mestier L, Brixi H, Gincul R, Ponchon T, Cadiot G. Updating the management of patients with rectal neuroendocrine tumors. Endoscopy. 2013 Dec;45(12):1039-46. doi: 10.1055/s-0033-1344794.
https://www.ncbi.nlm.nih.gov/pubmed/24163193

Dr. Jorge Hernando, MD, PhD

Dr. Jorge Hernando is a Medical Oncologist at Vall d´Hebron University Hospital in Barcelona, Spain. Jorge obtained his MD degree in 2010, and the Specialty in Medical Oncology in 2016 at the Miguel Servet University Hospital in Zaragoza, Spain.

In 2017 he obtained his PhD and joined the Gastrointestinal and Endocrine Tumor Unit at Vall d´Hebron University Hospital. He is mainly committed to the clinical management of patients affected by gastrointestinal, neuroendocrine and endocrine malignancies. Jorge is involved in clinical and translational research projects at the Vall d´Hebron Institute of Oncology (VHIO) and he is also coordinator of the gastrointestinal and neuroendorine patient advocacy group.

Dr. Hernando is involved in professional societies including the American Society of Clinical Oncology (ASCO), European Society for Medical Onology (ESMO), European Neuroendocrine Tumor Society (ENETS) and Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE).

Relevant Publications

Capdevila J, Mayor R, Mancuso FM, Iglesias C, Caratu G, Matos I, Zafon C, Hernando J, et al. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol 2018:29(6):1454-1460.
https://www.ncbi.nlm.nih.gov/pubmed/29648575

Amair-Pinedo F, Matos I, Saurí T, Hernando J, et al. The treatment landscape and new opportunities of molecular targeted therapies in gastroenteropancreatic neuroendocrine tumors. Target Onol 2017;12(6):757-774.
https://www.ncbi.nlm.nih.gov/pubmed/29143176

Hernando-Cubero J, Matos-García I, Alonso-Orduña V, et al. The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. J gastrointest Cancer 2017;48(2):135-147.
https://www.ncbi.nlm.nih.gov/pubmed/28397102

Garcia NA, Hernando Cubero J, Alonso Orduña V, et al. Adenosquiamous Cell Carcinoma of the Rectum in a Gril: First Case Reported and Review of the Literature. J Pediatr Hematol Oncol 2015;37(6):e364-7.
https://www.ncbi.nlm.nih.gov/pubmed/26181422

Carmona-Bayonas A, Jimenez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, Ramchandani A, Martinez J, Hernando Cubero J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the linical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol 2015:33(5):465-71.
https://www.ncbi.nlm.nih.gov/pubmed/25559804

Hernando-Cubero J, Alonso-Orduña V, Hernandez-García A, et al. Brain metástasis in basaloid undifferentiated anal carcinoma: A case report. Oncol Lett 2014;7(4):1276-1278.
https://www.ncbi.nlm.nih.gov/pubmed/24944707

Dr. Mauro Cives, MD

Dr. Mauro Cives works as Assistant Professor of Medical Oncology in the Department of Biomedical Sciences and Human Oncology, University of Bari, Italy. He gained his MD degree and specialization degree in Medical Oncology at the University of Bari. From 2013 to 2016 Dr. Cives worked as Research Associate within the Neuroendocrine Program of the Moffitt Cancer Center & Research Institute, Tampa (FL, USA). Dr. Cives’ work focuses on the preclinical and clinical evaluation of innovative treatments for neuroendocrine tumors (NETs). In 2017, Dr. Cives was awarded by the European Neuroendocrine Tumor Society (ENETS) for the project “CAR-T cells for GEP-NETs”. Dr. Cives is co-author of over 30 peer-reviewed papers.

Relevant Publications

Cives M, Strosberg J. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018; ahead of print.

Cives M, Anaya DA, Soares H, Coppola D, Strosberg J. Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors. J Natl Cancer Inst. 2018;110(3):282-289.
https://www.ncbi.nlm.nih.gov/pubmed/29741649

Cives M, Quaresmini D, Rizzo FM, Felici C, D’Oronzo S, Simone V, Silvestris F. Osteotropism of neuroendocrine tumors: role of the CXCL12/ CXCR4 pathway in promoting EMT in vitro. Oncotarget. 2017;8(14):22534-22549.
https://www.ncbi.nlm.nih.gov/pubmed/28186979

Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C, Xu J, Soares K, Weiss MJ, Zheng L, Wolfgang CL, Cives M, Wong J, Wang W, Sun J, Shao C, Wang W, Tan H, Li J, Ni Q, Shen L, Chen M, He J, Chen J, Yu X. Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. J Clin Oncol. 2017;35(3):274-280.
https://www.ncbi.nlm.nih.gov/pubmed/27646952

Cives M, Rizzo F, Simone V, Bisceglia F, Stucci S, Seeber A, Spizzo G, Montrone T, Resta L, Silvestris F. Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition. Neuroendocrinology. 2016;103(3-4):321-34.
https://www.ncbi.nlm.nih.gov/pubmed/26227818

Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, Meeker A, Strosberg J. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016;23(9):759-67.
https://www.ncbi.nlm.nih.gov/pubmed/27552969

Strosberg JR,Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016;23(5):411-8.
https://www.ncbi.nlm.nih.gov/pubmed/27080472

Cives M, Kunz PL, Morse B, Coppola D, Schell MJ, Campos T, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg JR. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015;22(1):1-9.
https://www.ncbi.nlm.nih.gov/pubmed/25376618

Dr. Jaume Capdevila, MD

Dr. Jaume Capdevila obtained his medical degree from the University of Lleida, in Catalonia, Spain. In 2000-2001 he held a fellowship in the department of biochemistry and molecular biology at the University of Lleida. From 2002 to 2006 he attended a specialization in medical oncology at the Santa Creu i Sant Pau University Hospital, Barcelona and since 2006 served as medical oncologist at Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. Since early 2013 he is also leading the gastrointestinal and endocrine tumor unit at Teknon Cancer Institute. He is involved in research and treatment of patients with gastrointestinal cancer and endocrine tumors as well as in early-drug development. He has published over 82 articles in peer-reviewed journals and several book chapters.

He is an active member of several oncology societies (ASCO, ENETS, EORTC, SEOM, TTD, GEMCAD, GETNE, and GETHI) and actively participates in national and international trials. He is member of the advisory board of the European Neuroendocrine Tumor Society (ENETS), Secretary and Treasurer of the Spanish Task Force for neuroendocrine tumors (Grupo Español de Tumores Neuroendocrinos, GETNE) and funding member and Treasurer of the Spanish Task Force Group for Research in Orphan and Rare Tumors (Grupo Español de Tumores Huérfanos e Infrecuentes, GETHI). He is also a medical oncologist member of the Thyroid Cancer Working Group within the Spanish Society of Endocrinology and Nutrition (SEEN).

Relevant Publications

Capdevila J, Mayor R, Mancuso FF, Iglesias C, Caratù G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez C, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol. 2018 Jun 1;29(6):1454-1460. doi: 10.1093/annonc/mdy123.
https://www.ncbi.nlm.nih.gov/pubmed/29648575

Merino-Casabiel X, Aller J, Arbizu J, García-Figueiras R, González C, Grande E, Jiménez-Fonseca P, Sevilla MI, Capdevila J. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors.Clin Transl Oncol. 2018 May 15. doi: 10.1007/s12094-018-1881-9.
https://www.ncbi.nlm.nih.gov/pubmed/29766455

Sclafani F, Chau I, Cunningham D, Hahne JC, Vlachogiannis G, Eltahir Z, Lampis A, Braconi C, Kalaitzaki E, De Castro DG, Wotherspoon A, Capdevila J, Glimelius B, Tarazona N, Begum R, Lote H, Hulkki Wilson S, Mentrasti G, Brown G, Tait D, Oates J, Valeri N. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Sci Rep. 2018 Jan 23;8(1):1445. doi: 10.1038/s41598-018-19212-5.
https://www.ncbi.nlm.nih.gov/pubmed/29362371

Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martinez Del Prado MP, Diaz-Perez JA, Castellano D, Sevilla I, Lopez C, Alonso T, Garcia-Carbonero R. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Oncologist. 2018 Apr;23(4):422-432. doi: 10.1634/theoncologist.2017-0364.
https://www.ncbi.nlm.nih.gov/pubmed/29330208

Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Oncologist. 2018 Jul;23(7):766-e90. doi: 10.1634/theoncologist.2017-0144.
https://www.ncbi.nlm.nih.gov/pubmed/29242283

Amair-Pinedo F, Matos I, Saurí T, Hernando J, Capdevila J. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Target Oncol. 2017 Dec; 12(6):757-774. doi: 10.1007/s11523-017-0532-3. Review.
https://www.ncbi.nlm.nih.gov/pubmed/29143176

Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Grande E, Capdevila J, López C, Teule A, Garcia-Carbonero R; Spanish Neuroendocrine Tumor Group (GETNE). Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep. 2017 Sep 18;19(11):72. doi: 10.1007/s11912-017-0633-2. Review.
https://www.ncbi.nlm.nih.gov/pubmed/28920153

Capdevila J, Trigo JM, Aller J, Manzano JL, Adrián SG, Llopis CZ, Reig Ò, Bohn U, Cajal TRY, Duran-Poveda M, Astorga BG, López-Alfonso A, Martínez JM, Porras I, Reina JJ, Palacios N, Grande E, Cillán E, Matos I, Grau JJ. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). Eur J Endocrinol. 2017 Oct;177(4):309-317. doi: 10.1530/EJE-17-0243.
https://www.ncbi.nlm.nih.gov/pubmed/28687563

Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J. Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights.
Mol Oncol. 2017 Sep;11(9):1263-1272. doi: 10.1002/1878-0261.12099. Epub 2017 Jul 20.
https://www.ncbi.nlm.nih.gov/pubmed/28618197

Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P, Hörsch D, Tiensuu Janson E, Ramage J; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology. 2017;105(3):295-309. doi: 10.1159/000475526. Epub 2017 Apr 13.
https://www.ncbi.nlm.nih.gov/pubmed/28402980

Capdevila J, Ignacio Matos Garcia, Francesco M Mancuso, Carmela Iglesias, Paolo Nuciforo, Carles Zafon, Hector G. Palmer, Zighereda Ogbah, Laura Muiños, Carol Elaine Pena, Marcia S. Brose, Martin Schlumberger, Ana Vivancos; RNAseq analysis of the sorafenib phase III DECISION trial in differentiated thyroid cancer (DTC): Correlation with clinical outcome. 2017 ASCO Annual Meeting. Abstract No: 6083. Poster Session (Board #71). J Clin Oncol 35, 2017 (suppl; abstr 6083).
https://meetinglibrary.asco.org/record/145917/abstract

Ignacio Matos Garcia, Enrique Grande, Rocio Garcia-Carbonero, Carlos Lopez, Alexandre Teule, Capdevila J. A multicohort phase II study of durvalumab plus tremelimumab for the treatment of patients (PTS) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or lung origin (the DUNE trial-GETNE1601-).2017 ASCO Annual Meeting. Abstract No: TPS4146. Poster Session (Board #130b). J Clin Oncol 35, 2017 (suppl; abstr TPS4146).
https://meetinglibrary.asco.org/record/152659/abstract

Edward M. Wolin, Marianne Pavel, Jaroslaw B Cwikla, Alexandria T. Phan, Markus Raderer, Eva Sedlackova, Guillaume Cadiot, Jaume Capdevila, Lucy Wall, Guido Rindi, Catherine Lombard-Bohas, Nilani Liyanage, Xuan Mai Truong Thanh, Philippe Ruszniewski, Martyn E. Caplin, CLARINET Investigators; Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study.2017 ASCO Annual Meeting. Abstract No: 4089. Poster Session (Board #81). J Clin Oncol 35, 2017 (suppl; abstr 4089).
https://meetinglibrary.asco.org/record/152016/abstract

Enrique Sanz-Garcia, Ana Maria Martinez, Elena Elez, Guillem Argiles, Julieta Grasselli, Teresa Macarulla, Jaume Capdevila, Maria Alsina, Tamara Sauri, Cinta Hierro, Ignacio Matos, Helena Verdaguer, Analia Azaro, Stefania Landolfi, Javier Hernandez-Losa, Jordi Rodón, Paolo Nuciforo, Ana Vivancos, Rodrigo Dienstmann, Josep Tabernero. Survival determinants with matched targeted therapies in BRAF mutant metastatic colorectal cancer (mCRC). Doi: 10.1200/jco.2016.34.4_suppl.649 Journal of Clinical Oncology 34, núm. 4_ suppl (February 2016) 649.
https://meetinglibrary.asco.org/record/120674/abstract

Ignacio Matos, Carolina Ortiz, Elena Elez, Guillem Argiles, Julieta Grasselli, Teresa Macarulla, Jaume Capdevila, Maria Alsina, Tamara Sauri, Cinta Hierro, Helena Verdaguer, Enrique Sanz-Garcia, Ana Maria Martinez, Eloy Espin, Cristina Dopazo, Stefania Landolfi, Paolo Nuciforo, Ana Vivancos, Rodrigo Dienstmann, Josep Tabernero. Prognostic impact of primary tumor site location in metastatic colorectal cancer (mCRC). DOI: 10.1200/ jco. 2016.34.4_suppl.578 Journal of Oncology 34, no 4 suppl. February 2016 – 578.
https://meetinglibrary.asco.org/record/120633/abstract

Carolina Ortiz, Guillem Argilés, Elena Élez, Judit Matito, Leire Mendizabal, Deborah Lo Giacco, Francesco M Mancuso, Enrique Sanz-García, Teresa Macarulla, Maria Alsina, Jaume Capdevila, Tamara Saurí, Analia Azaro, Cristina Cruz, Cinta Hierro, Santiago Ramon y Cajal, Paolo Nuciforo, Jordi Rodón, Josep Tabernero, Ana Vivancos. Measuring the impact of Next Generation Sequencing (NGS) technique implementation in metastatic colorectal cancer (mCRC) drug development program. DOI: 10.1200/jco.2015.33.15_suppl. 3598.
https://meetinglibrary.asco.org/record/113470/abstract

Jaume Capdevila, Ana Vivancos, Xavier Matias-Guiu, Carmela Iglesias, Francesc Salva,Xavier Serres, Oscar Gonzalez, Enric Caubet, Jose Jimenez, Carles Zafon, Francesco M Mancuso, Ginevra Caratu, Clara Alvarez, Regina Mayor, Josep Tabernero. Genomic landscape of anaplastic thyroid cancer. DOI: 10.1200/ jco.2015.33.15_suppl.6033 Journal of Clinical Oncology 33, no 15 suppl (mayo 2015) 6033.
https://meetinglibrary.asco.org/record/112350/abstract

Capdevila J, Trigo Perez JM, Aller J, Manzano JL, Garcia Adrian S, Zafon C, Reig O, Bohn U, Cillan E, Duran M, Gonzalez Astorga B, Lopez A, Javier M, Porras I, Reina JJ, Palacios N, Grande E, Grau JJ. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). J Clin Oncol 32:5s, 2014 (suppl; abstr 6027).
https://meetinglibrary.asco.org/record/94688/abstract

Capdevila J, Martinez-Trufero J, Dalmau, E Alvarez-Escola C, Beltran M, Duran M, Gallegos I, Manzano JL, Mesia R, Pajares I, Fuentes Pradera J, Grau JJ, Reig O, Trigo JM, Grande E. Retrospective analysis of the safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer (MTC). J Clin Oncol 32, 2014 (suppl; abstr e17015).
https://meetinglibrary.asco.org/record/95649/abstract

Elez Fernandez ME, Argiles G, Matito J, Mendizabal L, Moreno D, Jimenez J, Hernandez-Losa J, Macarulla T, Capdevila J, Alsina M, Sauri T, Azaro A, Cruz Zambrano C, Landolfi S, Sanz E, Ramon y Cajal S, Nuciforo P, Rodon J, Tabernero J, Vivancos A. Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC). J Clin Oncol 32:5s, 2014 (suppl; abstr 3591).
https://meetinglibrary.asco.org/record/97193/abstract

Barriuso J, Bernal E, Guerra Pastrian L, Grande E, Castellano DE, Capdevila J, Alvarez-Escola C, Martinez J, Diaz E, Heredia V, Castell J, Feliu J, Burgos E, Mendiola M. Study of the gastroenteropancreatic neuroendocrine tumor (gep-net) microenvironment beyond angiogenesis: The role of lysyl oxidase-like 2 (LOXL2). J Clin Oncol 32:5s, 2014 (suppl; abstr 4109).
https://meetinglibrary.asco.org/record/94007/abstract

Feliu J, Garcia-Carbonero R, Capdevila J, Guasch I, Alonso V, Lopez C, Garcia-Alfonso P, Castañon C, Cerezo L, Sevilla I, Conill C, Quintana-Angel B, Sanchez ME, Lopez-Torrcilla J, Ghanem I,Maurel J. Phase II trial of panitumumab (P) plus mytomicin C (M), 5-fluorouracil (5-FU), and radiation (RT) in patients with squamous cell carcinoma of the anal canal (SCAC): Safety and efficacy profile—VITAL study, GEMCAD 09-02 clinical trial. J Clin Oncol 32:5s, 2014 (suppl; abstr 4034).
https://meetinglibrary.asco.org/record/93984/abstract

Salazar R, Capdevila J, Rosenberg R, Glimelius B, Willem de Waard J, Bibeau F, Klaase J, Chang GJ, Van Der Hoeven JJM, Bachleitner-Hofmann T, Midgley RA, Levine EA, Asano M, Ziebermayr R, Deck KB, Sington J, Law WL, Shbeeb I, Stork L, Marshall J. Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial. J Clin Oncol 32:5s, 2014 (suppl; abstr 3562).
https://meetinglibrary.asco.org/record/97234/abstract

Capdevila J, Landolfi S, Jimenez J, Grande E, Castellano DE, Barriuso J, Teixido C, Silberschmidt D, Montero MA, Palmer EG, Felip E, Tabernero J, Vivancos A. Molecular characterization of nonpancreatic neuroendocrine neoplasms (NENS): First description of mutations in the tumor suppressor gene (TSG) SMARCB1 in NENS of colorectal origin using next-generation sequencing (NGS). J Clin Oncol 31, 2013 (suppl; abstr 4135).
https://meetinglibrary.asco.org/record/83000/abstract

Grande E, Casanovas O, Earl J, Castellano DE, Garcia-Carbonero R, Teule A, Duran I, Fuster J, Sevilla I, Escudero P, Sastre J, García-Donas J, Ortega L, Diez JJ, Rivas AS, Capdevila J. sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis. J Clin Oncol 31, 2013 (suppl; abstr 4140).
https://meetinglibrary.asco.org/record/82915/abstract

Grande E, Castellano D, García-Carbonero R, Teulé A, Duran I, Fuster J, Sevilla I, Escudero P, Sastre J, Casanovas O, Ortega L, Earl J, Diez JJ, de Velasco G, Longo F, Navarro A, Pachón V, Carrato A, Salazar R, Capdevila J. Pazonet: a phase ii trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (nets) patients (pts), on behalf of the spanish task force for nets (getne). Ann Oncol (2012) 23 (suppl 9): ix376-ix382.
https://academic.oup.com/annonc/article/23/suppl_9/ix376/218579#35551300

Capdevila J, Sevilla I, Alonso V, Anton-Aparicio L, Jimenez Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso-Jara J, García Alfonso P. Efficacy and safety of somatuline autogel in combination with molecular targeted therapies (mtt) in neuroendocrine tumors (nets). Ann Oncol (2012) 23 (suppl 9): ix376-ix382.
https://academic.oup.com/annonc/article/23/suppl_9/ix376/218579#35551571

Pavel M, Wiedenmann B, Capdevila J, Valle JW, De Herder WW, Metzer C, Salazar R, Horsch D, Oberg K. Ramsete: a single-arm, multicenter, single-stage phase ii trial of rad001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in europe: analysis by tumor origin. Ann Oncol (2012) 23 (suppl 9): ix376-ix38
https://academic.oup.com/annonc/article/23/suppl_9/ix376/218579#35551275

Rosen LS, Goldman J, Stewart S, Hubbard JM, Roos M, Lin W, Shankar G, Capdevila J, Freas E, Leong S. A phase 1b study to evaluate the safety and pharmacology of the dual pi3k-mtor inhibitor gdc-0980 in combination with a fluoropyrimidine, oxaliplatin, and bevacizumab (bev) in patients with advanced solid tumors. Ann Oncol (2012) 23 (suppl 9): ix152-ix174
https://academic.oup.com/annonc/article/23/suppl_9/ix152/218399#35533056

Laquente B, Capdevila J, Martinez-Villacampa M, López C, Safont JM, Gómez A, Manzano JL, Grávalos C, Salazar R, Aranda Aguilar E. Neoadjuvant addition of bevacizumab to chemoradiation in rectal cancer: impact on angiogenic biomarkers. Ann Oncol (2012) 23 (suppl 9): ix528-ix540.
https://academic.oup.com/annonc/article/23/suppl_9/ix528/218738#35563699

Salazar R, Rosenberg R, Capdevila J, Moreno V, Nitsche U, Bachleitner-Hofmann T, Roepman P, Gafa R, Lanza G, Tian S, Simon I. Personalized treatment planning of stage ii and iiia colon cancer patients using genomic classifiers (coloprint/ msi-print). Ann Oncol (2012) 23 (suppl 4): iv5-iv18.
https://academic.oup.com/annonc/article/23/suppl_4/iv5/143501#94713674

Capdevila J, Sevilla I, Alonso V, Anton Aparicio L, Jimenez P, Grande E, Reina JJ, Manzano JL, Alonso-Guadalajara JD, Garcia Alfonso P. Evaluation of safety and efficacy of somatuline autogel in combination with molecular targeted therapies (MTT) in patients with neuroendocrine tumors (NETs): Data from one Spanish cohort. J Clin Oncol 30, 2012 (suppl; abstr e14671).
https://meetinglibrary.asco.org/record/71253/abstract

Dewdney A, Chau I, Capdevila J, Glimelius B, Cervantes-Ruiperez A, Tait DM, Brown G, Wotherspoon A, Gonzalez de Castro D, Hulkki Wilson S, Chua YJ, Wong R, Barbachano Y, Oates JR, Cunningham D. The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab. J Clin Oncol 30, 2012 (suppl; abstr e14088).
https://meetinglibrary.asco.org/record/74252/abstract

Martinez Villacampa M, Capdevila J, Manzano JL, Pericay C, Salazar R, López-López C, Losa F, Safont MJ, Gomez A, Alonso V, Escudero MP, Gallego Plazas J, Sastre J, Gravalos Castro C, Biondo S, Palacios A, Aranda E. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer. J Clin Oncol 30, 2012 (suppl; abstr 3571).
https://meetinglibrary.asco.org/record/68741/abstract

Grande Pulido E, Castellano DE, Garcia-Carbonero R, Teule A, Duran I, Fuster J, Sevilla I, Escudero P, Sastre J, Capdevila J; PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE)—NCT01280201. J Clin Oncol 30, 2012 (suppl; abstr 4119).
https://meetinglibrary.asco.org/record/71035/abstract

Rodriguez de Antona C, Grande Pulido E, Leandro-Garcia L, Barriuso J, Capdevila J, Jimenez P, Castelo B, Castellano DE, Longo F, Garcia-Donas J. Evaluation of CYP3A5, VEGF-a, and VEGFR2 polymorphisms as markers of sunitinib toxicity. J Clin Oncol 30, 2012 (suppl; abstr 10546).
https://meetinglibrary.asco.org/record/70687/abstract

Valverde CM, Aizpurua M, Capdevila J, Morales R, Nuñez I, Suarez C, LandolfI S, de Torres I, Carles J, Moline T, Romagosa C; Senescence, a new concept in pathologic response evaluation of rectal carcinomas (RC) after neoadjuvant treatment. J Clin Oncol 30, 2012 (suppl; abstr e21021).
https://meetinglibrary.asco.org/record/70854/abstract

Pavel ME, Wiedenmann B, Capdevila J, Reed N, Valle JW, Caglio S, May C, Comis S, Castellana R, de Herder WW, Metzner C, Salazar R, Hörsch D, Oberg KE; RAMSETE: A single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe. J Clin Oncol 30, 2012 (suppl; abstr 4122).
https://meetinglibrary.asco.org/record/70979/abstract

Dienstmann R, Sanchez-Olle G, Serpico D, Rodon Ahnert J, Saura C, Macarulla T, Fernandez,ME, Alsina M, Perez-Garcia JM, Capdevila J, Argiles G, Brana I, Cruz C, Azaro A, Moreno-Fernandez D, Aura C, Hernandez-Losa J, Vivancos A, Ramon y Cajal D, Tabernero J. Molecular profiling of patients (pts) with colorectal cancer (CRC) and matched targeted therapy (MTA) in phase I clinical trials. J Clin Oncol 30, 2012 (suppl; abstr 3014).
https://meetinglibrary.asco.org/record/69184/abstract

Prof. Wouter de Herder, MD, PhD

Prof. Wouter de Herder is professor of Endocrine Oncology at the Erasmus MC in Rotterdam, the Netherlands. In this University Hospital he is chairman of a multidisciplinary group for endocrine oncology (tumorwerkgroep endocriene tumoren) and he is head of the ENETS centre of excellence for neuroendocrine tumors. His major research interests are neuroendocrine and endocrine tumors.
Professor de Herder received his MD in 1985 and his PhD in 1990 from the Erasmus University in Rotterdam, the Netherlands.

He is a member of several international and Dutch national societies, such as the Dutch society for Endocrinology (NVE), the Endocrine Society (USA), the European Society of Endocrinology (ESE), European Neuroendocrine Tumor Society (ENETS) and the North American Neuroendocrine Tumor Society (NANETS). He served as a board member of the Dutch society for Endocrinology (NVE) (2009-2014). He served as chairman (2006-2008) and vice-chairman of ENETS (2008-2010; European Neuroendocrine Tumour Society). He is member of the advisory boards of ENETS and NANETS.

Prof. de Herder has (co-)published >400 peer-reviewed papers and book chapters and is a reviewer for many international journals.
He is a member of the editorial boards of Neuroendocrinology; Endocrinology, Diabetes & Metabolism Case Reports; Clinical Endocrinology and Endocrine-related Cancer. He is member of the Publishing and Communications Committee of the ESE and Editor of ESE News. Prof. de Herder has given >170 invited presentations at Dutch national and international meetings.

Relevant Publications

de Herder WW, Krenning EP, Malchoff CD, Hofland LJ, Reubi J-C, Kwekkeboom DJ, Oei HY, Pols HAP, Bruining HA, Nobels FRE, Lamberts SWJ (1994) Somatostatin receptor scintigraphy: Its value in tumor localization in patients with the Cushing syndrome caused by ectopic corticotropin and/or CRH production. Am J Med 96: 305-312.
https://www.ncbi.nlm.nih.gov/pubmed/8166148

van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ (2001) [123I]Metaiodobenzylguanidine and [111In]Octreotide Uptake in Benign and Malignant Pheochromocytomas. J Clin Endocrinol Metab 86: 685-693.
https://www.ncbi.nlm.nih.gov/pubmed/11158032

Feelders RA, Lamberts SW, Hofland LJ, van Koetsveld PM, Verhoef-Post M, Themmen AP, de Jong FH, Bonjer HJ, Clark AJ, van der Lely AJ, de Herder WW (2003) Luteinizing Hormone (LH)-Responsive Cushing’s Syndrome: The Demonstration of LH Receptor Messenger Ribonucleic Acid in Hyperplastic Adrenal Cells, which Respond to Chorionic Gonadotropin and Serotonin Agonists in Vitro. J Clin Endocrinol Metab 88: 230-7.
https://www.ncbi.nlm.nih.gov/pubmed/12519858

de Herder WW, Krenning EP, van Eijck CH, Lamberts SW (2004) Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas. Endocr Relat Cancer 11: 19-34.
https://www.ncbi.nlm.nih.gov/pubmed/15027883

Feenstra J, de Herder WW, ten Have SMTH, van den Beld AW, Feelders RA, Janssen JAMJL, van der Lely AJ (2005). Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365: 1644-1646.
https://www.ncbi.nlm.nih.gov/pubmed/15885297

Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JAMJL, Uitterlinden P, Hofland LJ, Lamberts SWJ, van der Lely AJ, de Herder WW (2005). Postoperative Evaluation of Patients with Acromegaly: Clinical Significance and Timing of Oral Glucose Tolerance Testing and Measurement of (Free) Insulin-Like Growth Factor I, Acid-Labile Subunit, and Growth Hormone-Binding Protein Levels. J Clin Endocrinol Metab 90: 6480-6489.
https://www.ncbi.nlm.nih.gov/pubmed/16159936

Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW, Hofland LJ. (2008) Correlation of in vitro and in vivo somatotrophic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy.J Clin Endocrinol Metab. 93: 1412-1417.
https://www.ncbi.nlm.nih.gov/pubmed/18211974

de Herder WW, van Schaik E, Kwekkeboom D, Feelders RA. (2011) New therapeutic options for metastatic malignant insulinomas. Clin Endocrinol (Oxf). 75(3): 277-284.
https://www.ncbi.nlm.nih.gov/pubmed/21649688

van Schaik E, van Vliet EI, Feelders RA, Krenning EP, Khan S, Kamp K, Valkema R, van Nederveen FH, Teunissen JJ, Kwekkeboom DJ, de Herder WW. (2011) Improved Control of Severe Hypoglycemia in Patients with Malignant Insulinomas by Peptide Receptor Radionuclide Therapy. J Clin Endocrinol Metab. 96(11): 3381-3389.
https://www.ncbi.nlm.nih.gov/pubmed/21917872

Kamp K, Damhuis RA, Feelders RA, de Herder WW (2012) Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas (GEP-NET) (2012). Endocr Relat Cancer. 19(1): 95-99.
https://www.ncbi.nlm.nih.gov/pubmed/22194442

Kvols L, Oberg KE, O’Dorisio T, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B (2012) Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a Phase II study. Endocr Relat Cancer. 19(5): 657-666.
https://www.ncbi.nlm.nih.gov/pubmed/22807497

Kamp K, Gumz B, Feelders RA, Kwekkeboom DJ, Kaltsas G, Costa FP, de Herder WW (2013). Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after 177Lu-octreotate. Endocr Relat Cancer. 20(6): 825-831.
https://www.ncbi.nlm.nih.gov/pubmed/24036133

Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD; Knowledge NETwork (2014). Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 21(3): R153-R163.
https://www.ncbi.nlm.nih.gov/pubmed/24322304

Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, Lecoq AL, Lecumberri B, Trivellin G, Salvatori R, Moraitis AG, Holdaway I, Kranenburg-van Klaveren DJ, Chiara Zatelli M, Palacios N, Nozieres C, Zacharin M, Ebeling T, Ojaniemi M, Rozhinskaya L, Verrua E, Jaffrain-Rea ML, Filipponi S, Gusakova D, Pronin V, Bertherat J, Belaya Z, Ilovayskaya I, Sahnoun-Fathallah M, Sievers C, Stalla GK, Castermans E, Caberg JH, Sorkina E, Auriemma RS, Mittal S, Kareva M, Lysy PA, Emy P, De Menis E, Choong CS, Mantovani G, Bours V, de Herder W, Brue T, Barlier A, Neggers SJ, Zacharieva S, Chanson P, Shah NS, Stratakis CA, Naves LA, Beckers A (2015). Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer. 22: 745-757.
https://www.ncbi.nlm.nih.gov/pubmed/26187128

Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, de Herder WW, Feelders RA, Krenning EP, Kwekkeboom DJ (2017). Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate (2017). Endocr Relat Cancer. 24(5):243-251.
https://www.ncbi.nlm.nih.gov/pubmed/28320783

Dr. Joakim Crona, MD, PhD

Dr. Joakim Crona is a resident in clinical oncology and associate professor in molecular oncology at Uppsala Academic Hospital, Sweden. He has had a particular interest for neuroendocrine tumors since more than eight years. This included successfully defending his thesis covering genetics of neuroendocrine tumors, as well as working as a physician at the clinic of endocrine oncology. Joakim has just returned from a short-term fellowship at the Pheochromocytoma/Paraganglioma Program, US National Institutes of Health. He plans a future career in the field of endocrine oncology that will unite clinical science with molecular biology, aiming at improving treatment of patients with these rare diseases.

Relevant Publications

Crona J, Norlen, O, Antonodimitrakis P, Welin S, Stålberg P, Eriksson B. Multiple and Secondary Hormone Secretion in Patients with Metastatic Pancreatic Neuroendocrine Tumours. Epub December 14 2015, Journal of Clinical Endocrinology & Metabolism.
https://www.ncbi.nlm.nih.gov/pubmed/26672633

Crona J, Backman S, Maharjan R, Mayrhofer M, Stålberg P, Isaksson A, Hellman P, Björklund P. Spatio-temporal heterogeneity characterize the genetic landscape of pheochromocytoma and defines early events in tumorigenesis. Epub May 19 2015, Clinical Cancer Research.
https://www.ncbi.nlm.nih.gov/pubmed/25991818

Crona J, Gustavsson T, Norlén O, Edfeldt K, Åkerström T, Westin G, Hellman P, Björklund P, and Stålberg P. Somatic mutations and genetic heterogeneity at the CDKN1B locus in Small Intestinal Neuroendocrine Tumours. Epub Jan 14 2015, Annals of Surgical oncology.
https://www.ncbi.nlm.nih.gov/pubmed/25586243

Crona J, Delgado Verdugo A, Maharjan R, Stålberg P, Granberg D, Hellman P, Björklund P. Somatic Mutations in H-RAS in Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing. Epub May 2 2013, Journal of Clinical Endocrinology & Metabolism.
https://www.ncbi.nlm.nih.gov/pubmed/23640968

Delgado Verdugo A, Crona J, Starker LF, Stalberg P, Akerström G, Westin G, Hellman P, Bjorklund P. Global DNA methylation patterns in small intestinal neuroendocrine tumors (SI-NETs). Epub Nov 5 2013, Endocrine Related Cancer.
https://www.ncbi.nlm.nih.gov/pubmed/24192231

Prof. Kjell Öberg, MD, PhD

Dr. Kjell Öberg is Professor of Endocrine Oncology at the Medical Faculty of Uppsala University. He was the former head of the Department of Endocrine Oncology, University Hospital, and he is a specialist in endocrinology and internal medicine. He founded the Department of Endocrine Oncology at Uppsala University Hospital and has 40 years’ experience in the field of neuroendocrine tumors. Between 1986 and 1992 he was clinical associate director of the Ludwig Institute for Cancer Research. From 1998 to 2002 he was chairman of the Department of Medical Sciences at the Medical Faculty of Uppsala University. July 2002 until June 2008 he was the Dean of the Medical Faculty. He was the chairman of the Centre of Excellence of Endocrine Tumors and Vice chairman of the Department of Endocrine Oncology, University Hospital, Uppsala until May 2013, at present time he is senior advisor at the same department. Currently, Adjunct Professor of Surgery at Vanderbilt University, Nashville, USA.

Dr. Öberg was one of the founders and coordinator of the European Neuroendocrine Tumor Network (ENET) 1995-2000 and was past chairman of the Nordic Neuroendocrine Tumor Group. He has pioneered the treatment of carcinoid tumor patients with interferon and somatostatin analogues and developed assays for tumor markers such as Chromogranin A and radiological procedures, including specialized PET scans.

In 1988 he was the first to describe a genetic deletion in multiple endocrine neoplasia Type 1 (MEN1). Dr. Öberg has given many hundreds of presentations at international meetings and published more than 500 papers within his research field, H-factor 67 and 14,850 citations. In addition he is the author of numerous chapters on Carcinoid tumors in several international textbooks including William’s Textbook of Endocrinology, Leslie de Groot’s Textbook of Endocrinology, Clinical Endocrinology and Fordtran’s Textbook of Gastroenterology. Dr. Öberg is Editor-in Chief of World Journal of Gastroenterolgy (WJG).

In 1991 Dr. Öberg received the European Interferon Research reward. In 2003 he received the award “Eminent Scientist Year 2003” by the International Research Promotion Council (IRPC) and World Scientist Forum and in 2004 he was awarded the European Gold Medal in Endocrinology from the English Endocrine Society. In November 2006 he received the Harry Boström Award Lecture at Swedish Medical Society, and in 2011 the University Hospital Clinical Research Award. In 2014 he received the Rudbeck Medallion for excellence in research and the Life Time Achievement Award from North American Neuroendocrine Society. January 2017 Dr. Öberg was awarded with The Swedish Endocrine Society Gold Medal for prominent research and clinical activities and in March 2017 he received Lifetime Achievement Award by European Neuroendocrine Tumor Society (ENETS). In October of 2017, Lifetime Achievement from Asian Pacific Neuroendocrine Tumor Society (AP-NETS).

Dr. Öberg is a member of the Royal Society of Sciences, member of Swedish Society of Medical Research, Honorary member of Finnish Oncology Society, Finnish Endocrine Society and Honorary member of Spanish Neuroendocrine NET-work. Dr. Öberg is Vice President of ENETS since March 2012 and also a member of NANETS Advisory Board as well as several other national and international research and scientific boards and many scientific journal review boards.

Prof. Marianne Pavel, MD

Prof. Marianne Pavel is the Chair of Endocrinology at the Department of Medicine 1, University of Erlangen, Germany. Board certified as a specialist in internal medicine in 2000 and endocrinology/diabetes in 2001; she was appointed as Vice Head of the Division of Endocrinology and Metabolism at the Friedrich-Alexander University Erlangen in 2001. She took a position as an Assistant Director at the Charité University Hospital, Berlin in 2007 and was conferred a Professorship for NET Disease at the Charité University in 2010. In 2009, under her guidance, the NET Center at the Charité University was certified as one of the first ENETS Centers of Excellence.

Her major focus in medicine is neuroendocrine tumors for more than 20 years. She has conducted numerous clinical trials in the field of NET. She is involved in the activities from ENETS since 2005 and is first author of the 2012 and the updated 2016 “ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary”. Since April 2014 she is a member of the Executive Committee of ENETS and has recently been elected as chair of ENETS up from 2020. She is involved in scientific and educational activities in NET from different societies including German Cancer Foundation and ESMO.

Relevant Publications

Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer. 2018 Mar;25(3):309-322. doi: 10.1530/ERC-17-0455.
https://www.ncbi.nlm.nih.gov/pubmed/29330194

Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1411-1422. doi: 10.1016/S1470-2045(17)30471-0.
https://www.ncbi.nlm.nih.gov/pubmed/28838862

Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol. 2017 Jul 1;28(7):1569-1575. doi: 10.1093/annonc/mdx193.
https://www.ncbi.nlm.nih.gov/pubmed/28444114

Pavel ME, Becerra C, Grosch K, Cheung W, Hasskarl J, Yao JC. Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial. Clin Pharmacol Ther. 2017 Apr;101(4):462-468. doi: 10.1002/cpt.559.
https://www.ncbi.nlm.nih.gov/pubmed/28032910

Lamarca A, Walter T, Pavel M, Borbath I, Freis P, Nuñez B, Childs A, McNamara MG, Hubner RA, Garcia-Carbonero R, Meyer T, Valle JW, Barriuso J. Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. J Natl Cancer Inst. 2017 Jan 27;109(5). pii: djw277. doi: 10.1093/jnci/djw277.
https://www.ncbi.nlm.nih.gov/pubmed/28130474

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O’Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
https://www.ncbi.nlm.nih.gov/pubmed/28076709

Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017 Jan;35(1):14-23.
https://www.ncbi.nlm.nih.gov/pubmed/27918724

Kulke M, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, J. Brase C, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC; A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2017 Jun 1;28(6):1309-1315. doi: 10.1093/annonc/mdx078.
https://www.ncbi.nlm.nih.gov/pubmed/28327907

Merola E, Pavel M, Panzuto F, Capurso G, Cicchese N, Rinke A, Gress T, Iannicelli E, Prosperi D, Pizzichini P, Prasad V, Kump P, Lipp R, Partelli S, Falconi M, Wiedenmann B, Delle Fave G; Functional Imaging in the Follow-up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. J Clin Endocrinol Metab. 2017 May 1;102(5):1486-1494. doi: 10.1210/jc.2016-3732.
https://www.ncbi.nlm.nih.gov/pubmed/28324047

Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, Cuthbertson DJ, Dobson R, Grozinsky-Glasberg S, Steeds RP, Dreyfus G, Pellikka PA, Toumpanakis C. Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement.J Am Coll Cardiol. 2017 Mar 14;69(10):1288-1304. doi: 10.1016/j.jacc.2016.12.030.
https://www.ncbi.nlm.nih.gov/pubmed/28279296

Yao J, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries E, Tomassetti P, Hobday T, Pommier R, Öberg K. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers from the Randomized, Phase 3 RADIANT-3 Study. J Clin Oncol. 2016 Nov 10;34(32):3906-3913.
https://www.ncbi.nlm.nih.gov/pubmed/27621394

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 5;387(10022):968-77. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.
https://www.ncbi.nlm.nih.gov/pubmed/26703889

Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Öberg K; and all other Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172-85. doi: 10.1159/000443167.
https://www.ncbi.nlm.nih.gov/pubmed/26731013

Caplin M, Pavel M, Cwikla JB, Phan A, Raderer M, Sedlackova E, Cadiot G, Wolin E, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P. Antitumor effects of lanreotide for pancreatic and intestinal neuroendocrine tumors: the CLARINET open-label extension study. Endocr Relat Cancer. 2016 Mar;23(3):191-9. doi: 10.1530/ERC-15-0490.
https://www.ncbi.nlm.nih.gov/pubmed/26743120

Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015 Sep;16(9):e435-46. doi: 10.1016/S1470-2045(15)00186-2.
https://www.ncbi.nlm.nih.gov/pubmed/26370353

Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, Barriuso J, Pavel M, O’Toole D, Walter T; other Knowledge Network members. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015 Aug;22(4):657-64. doi: 10.1530/ERC-15-0119.
https://www.ncbi.nlm.nih.gov/pubmed/26113608

Dilz LM, Denecke T, Steffen IG, Prasad V, von Weikersthal LF, Pape UF, Wiedenmann B, Pavel M. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer. 2015 Jul;51(10):1253-62. doi: 10.1016/j.ejca.2015.04.005.
https://www.ncbi.nlm.nih.gov/pubmed/25935542

Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Oct 16;371(16):1556-7. doi: 10.1056/NEJMc1409757.
https://www.ncbi.nlm.nih.gov/pubmed/25317881

Pavel M, Hainsworth D, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Van Cutsem E, Yao YC, for the RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT 2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378(9808):2005-12.
https://www.ncbi.nlm.nih.gov/pubmed/22119496

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):514-23.
https://www.ncbi.nlm.nih.gov/pubmed/21306238

Dr. Teresa Alonso Gordoa, MD

Dr. Teresa Alonso Gordoa is a Medical Oncologist at the Medical Oncology Department of the Hospital Universitario Ramón y Cajal in Madrid. She finalized the degree of medicine by the University of Navarre in 2008 and the medical oncology specialization by the Hospital Universitario Clínico San Carlos in 2013. She is specialized in the care of patients with genitourinary, germ cell and endocrine tumors and in the early drug development unit. In addition, she is a member of the Spanish Society of Medical Oncology (SEOM), the European Society for Medical Oncology (ESMO), the Spanish Society of Genitourinary Oncology (SOGUG), the Germ Cell Group (GG) and the Spanish Group of Neuroendocrine Tumors (GETNE). She participates actively in research projects and clinical trials with international impact. She is a member of the honorary faculty of the University of Alcalá and a reviewer of indexed international journals. She has presented communications in national and international congresses and has participated in the publication of scientific articles in national and international journals.

Relevant Publications

Javier Molina Cerrillo; Teresa Alonso Gordoa; Olga Martínez Sáez; Enrique Grande. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors. The Oncologist. 21 – 6, pp. 701 – 707. 06/2016.
https://www.ncbi.nlm.nih.gov/pubmed/27107003

Teresa Alonso Gordoa; Juan José Díez; Javier Molina; Pablo Reguera; Olga Martínez; Enrique Grande. An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Rare Cancers and Therapy. 3, pp. 13 – 33. 11/07/2015.
https://www.ncbi.nlm.nih.gov/pubmed/27182476

Teresa Alonso Gordoa; Jaume Capdevila; Enrique Grande. GEP NETs Biotherapy in Neuroendocrine Tumors. European Journal of Endocrinology. 172 – 1, pp. R31 – R46. 01/2015.
https://www.ncbi.nlm.nih.gov/pubmed/25430657

Pablo Gajate; Teresa Alonso Gordoa; Olga Martínez Sáez; Javier Molina Cerrillo; Enrique Grande. Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms. Clin Transl Oncol. 09/11/2017.
https://www.ncbi.nlm.nih.gov/pubmed/29124519

Prof. Martyn Caplin, BSc Hons, DM, FRCP

Prof. Martyn Caplin is Professor of Gastroenterology & GI Neuroendocrinology at the Royal Free Hospital and University College London. He leads The Royal Free Hospital’s “European Neuroendocrine Tumour Society’s Centre of Excellence”. Furthermore, he leads scientific and clinical research programmes into neuroendocrine tumours. In addition to being the Chairman ENETS (2014-2016), he now serves on its advisory board. He has been with ENETS since its foundation in 2004. He received a Lifetime Achievement Award from the UK & Ireland Neuroendocrine Tumour Society (UKI NETS) in recognition of his clinical leadership and research in the field of NETs. He is a founder and Past-Chairman of the UK & Ireland Neuroendocrine Tumour Society. 2006-2014 he was a member of the National Cancer Research Institute (NCRI) Upper-G.I. Cancer Committee and he is a Past-Chairman of the NCRI Neuroendocrine Tumour group. He is a Patron of the NET Patient Foundation. He has published over 200 peer-reviewed papers, written multiple book chapters and co-authored two books. He regularly lectures both nationally and internationally. 2006-2012 he was the clinical lead for “NHS Evidence” for Gastroenterology and Liver diseases (under the auspices of NICE), chairing annual evidence updates into gastrointestinal and liver disorders.

Collaborations